Business
Easton Pharmaceuticals and Partner BMV Medica Announces Sales & Distribution Negotiations With Womens Health-Focused Multi-National European Pharma Company
Easton Pharmaceuticals and Partner BMV Medica Announces Sales & Distribution Negotiations With Womens Health-Focused Multi-National European Pharma Company.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals and Partner BMV Medica Announces Sales & Distribution Negotiations With Womens Health-Focused Multi-National European Pharma Company\n \n \nEaston Pharmaceuticals and Partner BMV Medica Announces Sales & Distribution Negotiations With Womens Health-Focused Multi-National European Pharma Company\n\nProvide Regulatory Filing Update for Their Patented Women's Health Diagnostic Product, VS-Sense For The Mexico Market\n\n \n TORONTO, ON--(Marketwired - Apr 6, 2016) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH), together with their commercial alliance partner BMV Medica SA de CV, provides Mexican Regulatory Filing Update for its Patented Women's Health Diagnostic Product, VS-Sense For The Mexican Market. In addition, Easton / BMV announces it has initiated partnership negotiations for Mexican Sales & Marketing of its suite of women's health products with a multi-national Europe-based pharma company operating in over 38 countries world-wide.\n As previously announced in February, Easton / BMV were notified through Ackerman Pharma, the filing of its patented, point-of-care, VS-Sense Diagnostic test through \"fast-track\" third-party authorized reviewer Defi Latina Healthcare, S.A. de C.V. for regulatory approval in Mexico. As of today, final, corrected documents are expected from the Israeli manufacturer to complete the filing, and are expected within a week. \n Since submission, Defi Latina -- one of only few authorized third-party reviewers licensed by the Ministry of Health in Mexico to review and pre-approve Regulatory dossiers prior to submission -- has and continues to undergo a detailed review of the regulatory dossier for VS-Sense, a unique point-of-care vaginal discharge diagnostic test called VagiSan in Mexico. VagiSan is the brand Easton/BMV plan to launch in Mexico and Latin America, and is the same product Bayer had licensed and launched recently in Europe under its brand Canestest, and Prestige Distribution in the US has launched under its brand Monistat, with multi-million dollars in sales.\n In Mexico, the \"fast-track\" review process through authorized third-party reviewers can speed up approval times from several years to a few short months if the regulatory dossier is complete. Easton / BMV have worked diligently over recent months with the manufacturer CommonSense LT...